# Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT07709767** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tang-Du Hospital** · enrollment: 21 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Retlirafusp Alfa
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **PROCEDURE:** Radical Surgery

## Key facts

- **NCT ID:** NCT07709767
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-30
- **Primary completion:** 2028-12-30
- **Final completion:** 2032-08-30
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07709767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07709767, "Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07709767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*